S. Solomon

发表

The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

M. Solh, D. Speckhart, S. Solomon, 2020, Blood advances.

Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

C. Granger, C. Bode, K. Huber, 2008, Circulation.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

J. Cortes, M. Tallman, J. Kolitz, 2014, Blood.

Plasma fibronectin during myocardial ischemia‐reperfusion: Effects of magnesium, diltiazem, and a novel Mac‐1 inhibitor

W. Herzog, P. Gurbel, V. Serebruany, 1998, American journal of hematology.

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.

A. Barrett, R. Childs, E. Read, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia

G. Schiller, G. Roboz, S. Solomon, 2020, Leukemia & lymphoma.

with untreated AML cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of

J. Cortes, M. Tallman, J. Kolitz, 2014 .

Extramedullary acute myelogenous leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Blood reviews.

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

K. Ballen, O. Ringdén, D. Rizzieri, 2020, Biology of Blood and Marrow Transplantation.

elastase diminished sensitivity to the antiproliferative effects of neutrophil Clonal dominance of chronic myelogenous leukemia is associated with

K. Rezvani, K. Keyvanfar, N. Hensel, 2013 .

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

D. Maloney, F. Hernandez-Ilizaliturri, Timothy R. Mack, 2022, The Lancet.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

P. Riedell, L. Gordon, A. D’Andrea, 2022, The Lancet. Oncology.

Reconstitution of FOXP 3 regulatory T cells ( Tregs ) after CD 25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease

K. Rezvani, A. Barrett, V. Ghetie, 2007 .

Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

K. Rezvani, A. Barrett, V. Ghetie, 2007, Blood.

CD4+CD25+ T cells: friends or foes?

S. Solomon, 2004 .

Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.

J. Cortes, J. Kolitz, R. Stone, 2016 .

Low Dose Subcutaneous Alemtuzumab and Prophylactic Donor Lymphocyte Infusion Results in Favorable Outcomes for High Risk Recipients of Unrelated Donor Allogeneic Transplants.

S. Solomon, A. Bashey, L. Morris, 2009 .

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

I. Lowy, R. Soiffer, E. Ball, 2009, Blood.

CTLA 4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

I. Lowy, R. Soiffer, E. Ball, 2009 .

Selective depletion strategies in allogeneic stem cell transplantation.

A. Barrett, S. Mielke, S. Solomon, 2005, Cytotherapy.

Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and cellular therapy.

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.

J. Michálek, A. Barrett, V. Ghetie, 2002, Cytotherapy.

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

M. Gobbi, R. Hills, F. Giles, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Reconstituting T Cell Immunity Following Hematopoietic Stem Cell Transplantation

A. Barrett, S. Solomon, 2003 .

Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation

N. Young, A. Barrett, R. Childs, 2003, Bone Marrow Transplantation.

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.

J. Cortes, J. Kolitz, J. Lancet, 2021, Blood advances.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

G. Tricot, D. Reece, D. White, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

K. Rezvani, A. Barrett, E. Gostick, 2008, Blood.

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

J. Cortes, J. Kolitz, R. Stone, 2016 .

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.

J. Cortes, J. Kolitz, J. Lancet, 2021, The Lancet. Haematology.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

J. Esteve, F. Baron, M. Labopin, 2019, Haematologica.

Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevanceof Certain Hemostatic Factors During the Occlusion Phase

W. Herzog, P. Gurbel, V. Serebruany, 2004, Journal of Thrombosis and Thrombolysis.

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

S. Solomon, A. Bashey, L. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inferences for current chronic graft-versus-host-disease free and relapse free survival

S. Solomon, Xu Zhang, Connie A. Sizemore, 2022, BMC Medical Research Methodology.

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

A. Barrett, N. Hensel, V. Ghetie, 2005, Blood.

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

M. Solh, S. Solomon, A. Bashey, 2021, Advances in hematology.

Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

S. Solomon, A. Bashey, L. Morris, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

K. Dorritie, W. Wierda, T. Siddiqi, 2020 .

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).

M. Solh, S. Solomon, A. Bashey, 2020, Leukemia research.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Robert K. Stuart, Antje Hoering, Arthur C. Louie, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

P. Venugopal, D. Neuberg, M. Tallman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Michael L. Wang, L. Gordon, D. Maloney, 2020, The Lancet.

Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase.

Katayoun Rezvani, Hiroshi Fujiwara, K. Rezvani, 2003, Blood.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Catastrophic failures of freezing bags for cellular therapy products: description, cause, and consequences.

R. M. Childs, E. Read, C. Carter, 2002, Cytotherapy.

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

P. Venugopal, M. Buyse, G. Gaidano, 2021, Cancer.

Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore?

S. Solomon, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2016, Advances in hematology.

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

S. Solomon, A. Bashey, L. Morris, 2011 .

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lineage‐specific engraftment and outcomes after T‐cell‐depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning

R. Childs, E. Read, S. Leitman, 2005, British journal of haematology.

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Si

Ocn, S. Jacobson, S. Solomon, 2013 .

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

A. Nademanee, R. Champlin, S. Solomon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.

S. Solomon, A. Bashey, L. Morris, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

S. Solomon, A. Bashey, L. Morris, 2014 .

HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide.

Shannon R. McCurdy, M. Grunwald, Stephanie J. Lee, 2021, Blood.

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with Thymoglobulin for myeloid malignancy.

M. Grunwald, O. Ringdén, H. Lazarus, 2021, Transplantation and cellular therapy.

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.

D. Follmann, A. Barrett, N. Hensel, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

Michael L. Wang, L. Gordon, D. Maloney, 2018 .

Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML.

J. Cortes, J. Kolitz, J. Lancet, 2020 .

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

N. Geller, M. Perales, H. Heslop, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

C. Jacobson, N. Jain, L. Akard, 2021, Blood.

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program

H. Kent Holland, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)

M. Solh, S. Solomon, A. Bashey, 2021, Bone Marrow Transplantation.

Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Results of the BMT CTN 1301 Progress II Trial

N. Geller, M. Perales, H. Heslop, 2021 .

Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy.

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Association of Chronic Graft-versus-Host Disease with Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.

R. Gale, J. Pidala, L. Lekakis, 2022, Transplantation and cellular therapy.

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Differences in GVHD Characteristics Between Haploidentical Transplantation Using Post-Transplant Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.

M. Solh, S. Solomon, A. Bashey, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

R. Vij, N. Callander, P. Moreau, 2023, The New England journal of medicine.

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Michael L. Wang, L. Gordon, D. Maloney, 2019, Blood.

K. Izutsu, M. Lunning, J. Braverman, 2022, Blood advances.

A Comparison Of Toxicity And Mobilization Efficacy Following Two Different Doses Of Cyclophosphamide For Mobilization Of Hematopoietic Stem Cells In Multiple Myeloma Patients

S. Solomon, A. Bashey, L. Morris, 2010 .

A Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization of Hematopoietic Stem Cells in Multiple Myeloma Patients.

S. Solomon, A. Bashey, L. Morris, 2009 .

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

M. Solh, S. Solomon, A. Bashey, 2015 .

High-dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

Robust Expansion of Viral Antigen-specific CD4+ and CD8+ T Cells for Adoptive T Cell Therapy Using Gene-modified Activated T Cells as Antigen Presenting Cells

K. Keyvanfar, J. Melenhorst, N. Hensel, 2006, Journal of immunotherapy.

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission

J. Cortes, J. Kolitz, G. Schiller, 2020 .

Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

A. Santoro, G. Martinelli, F. Ravandi, 2021 .

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

F. Hernandez-Ilizaliturri, K. Izutsu, M. Lunning, 2022, Blood.

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

P. Riedell, D. Maloney, D. Brander, 2023, The Lancet.

Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL

H. Kantarjian, N. Jain, B. Shah, 2021, Blood.

TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL

K. Dorritie, W. Wierda, T. Siddiqi, 2021, Hematological Oncology.

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant

M. Solh, S. Solomon, A. Bashey, 2023, Blood advances.

Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction

C. Granger, C. Bode, K. Huber, 2008, Circulation.

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

J. Cortes, J. Kolitz, R. Stone, 2018, Blood.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Transplantation with Post-transplant Cyclophosphamide for High-risk Acute Lymphoblastic Leukemia

S. Solomon, A. Bashey, D. Milton, 2017 .

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

S. Solomon, A. Bashey, L. Morris, 2012 .

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.

M. Lunning, E. Purev, M. Palomba, 2023, Blood.

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

S. Solomon, A. Bashey, L. Morris, 2014 .

T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor

S. Solomon, A. Bashey, S. Solomon, 2014, Bone Marrow Transplantation.

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

S. Kambhampati, H. Kantarjian, T. Kadia, 2018, Blood.